Dimensional Fund Advisors LP Has $3.07 Million Stock Position in Alector, Inc. (NASDAQ:ALEC)

Dimensional Fund Advisors LP trimmed its position in Alector, Inc. (NASDAQ:ALEC - Free Report) by 20.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 676,076 shares of the company's stock after selling 169,888 shares during the period. Dimensional Fund Advisors LP owned approximately 0.70% of Alector worth $3,069,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of ALEC. Vanguard Group Inc. raised its holdings in Alector by 12.0% in the first quarter. Vanguard Group Inc. now owns 4,912,578 shares of the company's stock worth $29,574,000 after purchasing an additional 526,037 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in Alector by 16.2% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 922,799 shares of the company's stock worth $5,555,000 after buying an additional 128,515 shares during the period. Acadian Asset Management LLC lifted its holdings in Alector by 32.8% during the second quarter. Acadian Asset Management LLC now owns 590,662 shares of the company's stock worth $2,681,000 after acquiring an additional 146,015 shares in the last quarter. Panagora Asset Management Inc. grew its stake in Alector by 61.7% in the second quarter. Panagora Asset Management Inc. now owns 355,318 shares of the company's stock valued at $1,613,000 after acquiring an additional 135,614 shares during the period. Finally, Bank of New York Mellon Corp increased its holdings in shares of Alector by 21.5% in the second quarter. Bank of New York Mellon Corp now owns 279,938 shares of the company's stock worth $1,271,000 after acquiring an additional 49,625 shares in the last quarter. Institutional investors own 85.83% of the company's stock.

Insider Buying and Selling at Alector

In other news, CEO Arnon Rosenthal sold 26,499 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $4.88, for a total transaction of $129,315.12. Following the completion of the transaction, the chief executive officer now directly owns 1,948,746 shares in the company, valued at $9,509,880.48. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CEO Arnon Rosenthal sold 26,499 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $4.88, for a total value of $129,315.12. Following the completion of the sale, the chief executive officer now owns 1,948,746 shares of the company's stock, valued at approximately $9,509,880.48. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Paula Hammond sold 10,500 shares of the business's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $5.06, for a total transaction of $53,130.00. Following the transaction, the director now owns 60,209 shares in the company, valued at approximately $304,657.54. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 58,222 shares of company stock worth $286,013. Insiders own 9.10% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on ALEC. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alector in a report on Tuesday, September 17th. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of Alector in a research note on Thursday, June 20th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Alector currently has an average rating of "Buy" and a consensus target price of $17.75.

Alector Trading Up 5.5 %

Shares of ALEC stock traded up $0.25 on Friday, hitting $4.80. 345,709 shares of the stock were exchanged, compared to its average volume of 625,378. The business has a 50-day moving average of $5.11 and a 200 day moving average of $5.22. Alector, Inc. has a fifty-two week low of $3.66 and a fifty-two week high of $8.90. The firm has a market capitalization of $467.14 million, a P/E ratio of -2.67 and a beta of 0.68.

Alector (NASDAQ:ALEC - Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.09. The company had revenue of $15.08 million during the quarter, compared to analysts' expectations of $16.04 million. Alector had a negative net margin of 290.66% and a negative return on equity of 102.63%. During the same period last year, the business earned $0.02 EPS. As a group, research analysts forecast that Alector, Inc. will post -1.92 EPS for the current fiscal year.

Alector Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.